华蟾素抗肿瘤研究进展

Progress of Cinobufacini Antitumor Research

华蟾素(Cinobufacini)作为我国自主研制的抗肿瘤中药制剂,在临床治疗恶性肿瘤中其疗效得到初步认可。实验及临床研究显示华蟾素制剂体内外抗肿瘤活性显著,作用机制复杂且未完全明确。华蟾素在胰腺癌、肺癌、肝癌、淋巴瘤等恶性肿瘤中均表现出抑制肿瘤发生发展,缓解癌性疼痛,改善中晚期肿瘤患者生活质量,控制副反应发生率等功效。应进一步探究华蟾素制剂治疗恶性肿瘤的作用机制以及主要抗肿瘤有效成分,以期能为临床治疗提供更多依据。文章从华蟾素主要有效成分、抗肿瘤作用机理以及临床疗效三个方面综述华蟾素制剂研究进展。

Cinobufacini as a Chinese independently developed Traditional Chinese medicine preparation,the efficacy on clinical treatment of malignant tumor has been preliminarily recognized. Experimental and clinical studies showed that cinobufacini have significant antitumor activity both in vitro and in vivo, but the mechanism is complex and not completely clear. Cinobufacini exhibits the efficacy of inhibiting tumor development, relieving cancerous pain, improving the quality of life of patients, and controlling the incidence of side effects in malignant tumors of pancreatic cancer, lung cancer, liver cancer, lymphoma and so on.The mechanism of treat on malignant tumors and the active components of cinobufacini should be further explored, In order to provide more evidence for clinical treatment. The study summarizes the research progress of cinobufacini preparations from three aspects： the main active components, the anti-tumor mechanism and the clinical efficacy.